Literature DB >> 33102801

Cost of nitric oxide therapy in neonates.

Emily Hoyle1, Hannah Spierson1, David Cordon1, Joanne Brady1, Nimish V Subhedar.   

Abstract

A retrospective observational cohort study was performed to review the cost of inhaled nitric oxide (iNO) therapy in a UK neonatal intensive care setting over a 4-year period. 188 neonates with a median (IQR) gestational age and birth weight of 27 (24-37) weeks and 980 (695-2812) g, respectively, were treated with iNO. The median (IQR) duration of iNO therapy was 60 (22-129) hours. The mean cost of iNO therapy was approximately £820 per baby treated equivalent to £8.50 per hour of therapy. Alternative pricing models suggested a calculated cost of iNO therapy of between approximately £950 and £1350 per baby. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  data collection; neonatology

Year:  2020        PMID: 33102801      PMCID: PMC7554454          DOI: 10.1136/bmjpo-2020-000776

Source DB:  PubMed          Journal:  BMJ Paediatr Open        ISSN: 2399-9772


We conducted a study to determine the cost of inhaled nitric oxide (iNO) therapy in a neonatal intensive care unit and provide novel data on the current cost of such therapy in the UK. iNO is a selective pulmonary vasodilator that has become part of the standard management for neonatal hypoxaemic respiratory failure and/or pulmonary hypertension.1 It is licensed for use in the treatment of newborn infants ≥34 weeks’ gestation with hypoxic respiratory failure2 but is also commonly used off-label in preterm infants <34 weeks’ gestation. There are limited, historical, data relating to the overall costs of iNO therapy in neonates and none providing information at an individual baby level.3 4 A retrospective observational cohort study was performed to review the use of iNO in our neonatal unit to calculate the costs of providing therapy in a neonatal care setting. Our institution is a tertiary-level regional referral centre, accepting approximately 1000 term and preterm admissions per annum. Babies with antenatally diagnosed structural cardiac defects are delivered and receive initial stabilisation at our institution, prior to transfer to a cardiac surgical centre. In our unit, iNO is used in the management of ventilated term and preterm infants with hypoxaemic respiratory failure. We do not offer an extracorporeal membrane oxygenation service. All newborn infants who were treated with iNO at Liverpool Women’s Hospital over a 4-year period (between April 2016 and March 2020 inclusive) were included and identified using local data submitted to the European iNO Registry (https://www.medscinet.net/ino/). Information on the total cost of iNO therapy, including number of gas cylinders used, rental charges for cylinders, monitoring/delivery equipment and cost of consumables was obtained from hospital finance records for this period. Using this information, we calculated the mean annual actual cost of providing iNO therapy using our commercial supplier which charged on the basis of total number of individual items used (BTG Gases, SOL Group, Monza, Italy). We also created two models to reflect alternative pricing structures offered by the other UK supplier of iNO during the study period (INO Therapeutics, Sittingbourne, UK). Model A provided a complete rental package for iNO gas and all equipment using an hourly charge basis of £23.10 per hour, which included a volume discount of 15% based on the previous year’s usage, capped at a maximum of 96 hours treatment. Model B charged on the same basis as our own supplier with separate elements to be purchased including the gas itself, cylinder rental charge and cost of consumables. One hundred and eighty-eight neonates were treated with iNO during this study period; seven babies received two courses. Their median (IQR) gestational age and birth weight were 27 (24–37) weeks and 980 (695–2812) g, respectively. During this time, a total of 18 078 hours of iNO therapy was used. The median (IQR) duration of iNO therapy was 60 (22–129) hours. The cost of iNO therapy and the calculated costs using the two other models are shown in table 1.
Table 1

Actual cost of iNO and comparison with other UK pricing models

Actual costPricing model APricing model B
Mean cost (per annum)£38 414£44 985£63 308
Mean cost (per hour)£8.50£9.95£14.00
Mean cost (per treatment episode)£787.98£922.76£1298.63
Mean cost (per baby treated)£817.32£957.12£1346.98

iNO, inhaled nitric oxide.

Actual cost of iNO and comparison with other UK pricing models iNO, inhaled nitric oxide. There are relatively few studies describing the cost of individual drugs commonly used in neonatal practice. Along with surfactant, our data indicate that iNO is one of the most expensive drugs routinely offered to neonates.5 Data from this study are likely to be useful to individual neonatal providers and healthcare commissioners to inform budgeting and expenditure. Additionally, an accurate estimation of the overall costs of iNO therapy is essential for health economic research studies evaluating the cost-effectiveness of therapeutic interventions in neonatal care.
  4 in total

1.  Cost of inhaled nitric oxide therapy in neonates.

Authors:  Nimish V Subhedar; Praveen Jauhari; Ramkumar Natarajan
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

Review 2.  Inhaled nitric oxide therapy for pulmonary disorders of the term and preterm infant.

Authors:  Gregory M Sokol; Girija G Konduri; Krisa P Van Meurs
Journal:  Semin Perinatol       Date:  2016-10       Impact factor: 3.300

3.  Inhaled nitric oxide in term/late preterm neonates with hypoxic respiratory failure: estimating the financial impact of earlier use.

Authors:  G Ganesh Konduri; Joseph Menzin; Molly Frean; Terry Lee; Jim Potenziano; Joel Singer
Journal:  J Med Econ       Date:  2015-05-07       Impact factor: 2.448

4.  Poractant Alfa Versus Beractant for Neonatal Respiratory Distress Syndrome: A Retrospective Cost Analysis.

Authors:  Sara Brown; Jeff Hurren; Heidi Sartori
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.